{"success":true,"data":{"pressRelease":{"id":"154949","rtpr_id":"nPn1Yq2CPa-20260929","ticker":"MDLN","exchange":"NASDAQ","all_tickers":["MDLN"],"title":"Medline Legal Alert: Medline (MDLN) Investors who Lost Money are Notified of the Ongoing Securities Fraud Investigation","author":"PR Newswire","published_at":"2026-09-29T10:05:00.032Z","article_body":"Medline Legal Alert: Medline (MDLN) Investors who Lost Money are Notified of the Ongoing Securities Fraud Investigation\nPR Newswire\n\nNEW YORK, Sept. 29, 2026\n\nBFA Law is investigating whether Medline Inc. committed securities fraud\nrelating to statements about Medline's manufacturing and product quality.\n\nNEW YORK, Sept. 29, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3728241497&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential\nsecurities fraud after its significant stock drops.\n\nIf you invested in Medline securities, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n.\n\nKey Details of the Medline ($MDLN) Class Action Investigation:\n\n * Investigation Overview: Securities fraud relating to Medline's statements\nabout its manufacturing and product quality.\n * Stock Declines: June 2, 2026 – 7% Stock Drop\n                            August 5, 2026 – 13% Stock Drop\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=399308703&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nWhy is Medline Being Investigated for Securities Fraud?\n\nMedline is a healthcare manufacturing and supply-chain company that retails\nand distributes medical and surgical products.\n\nBFA is investigating whether Medline misled investors about its manufacturing\nand product quality.\n\nWhy did Medline's Stock Drop?\n\nOn June 2, 2026, the FDA published a warning letter detailing Medline's\n\"significant violations of Current Good Manufacturing Practice regulations for\nfinished pharmaceuticals\" and stating that Medline \"failed to thoroughly\ninvestigate any unexplained discrepancy or failure of a batch or any of its\ncomponents to meet any of its specifications.\"\n\nFollowing that announcement, Medline shares fell approximately 7% on June 2,\n2026.\n\nThen, before market hours on August 5, 2026, Medline acknowledged that at\nleast some of remediation steps taken to address the issues in the FDA's\nwarning letter had \"result[ed] in earnings loss\" during the company's 2Q26\nearnings call.\n\nFollowing that announcement, Medline shares fell approximately 13% on August\n5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in Medline securities, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\n Shareholders are not responsible for any court costs or expenses of\nlitigation.  The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\"  One testimonial described the firm as \"nimble\nand entrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=1370031417&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/medline-legal-alert-medline-mdln-investors-who-lost-money-are-notified-of-the-ongoing-securities-fraud-investigation-302891857.html\n(https://www.prnewswire.com/news-releases/medline-legal-alert-medline-mdln-investors-who-lost-money-are-notified-of-the-ongoing-securities-fraud-investigation-302891857.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA2974561\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1Yq2CPa-20260929","title":"Medline Legal Alert: Medline (MDLN) Investors who Lost Money are Notified of the Ongoing Securities Fraud Investigation","author":"PR Newswire","ticker":"MDLN","created":"2026-09-29T10:05:00.032Z","tickers":["MDLN"],"exchange":"NASDAQ","article_body":"Medline Legal Alert: Medline (MDLN) Investors who Lost Money are Notified of the Ongoing Securities Fraud Investigation\nPR Newswire\n\nNEW YORK, Sept. 29, 2026\n\nBFA Law is investigating whether Medline Inc. committed securities fraud\nrelating to statements about Medline's manufacturing and product quality.\n\nNEW YORK, Sept. 29, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3728241497&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential\nsecurities fraud after its significant stock drops.\n\nIf you invested in Medline securities, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n.\n\nKey Details of the Medline ($MDLN) Class Action Investigation:\n\n * Investigation Overview: Securities fraud relating to Medline's statements\nabout its manufacturing and product quality.\n * Stock Declines: June 2, 2026 – 7% Stock Drop\n                            August 5, 2026 – 13% Stock Drop\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=399308703&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nWhy is Medline Being Investigated for Securities Fraud?\n\nMedline is a healthcare manufacturing and supply-chain company that retails\nand distributes medical and surgical products.\n\nBFA is investigating whether Medline misled investors about its manufacturing\nand product quality.\n\nWhy did Medline's Stock Drop?\n\nOn June 2, 2026, the FDA published a warning letter detailing Medline's\n\"significant violations of Current Good Manufacturing Practice regulations for\nfinished pharmaceuticals\" and stating that Medline \"failed to thoroughly\ninvestigate any unexplained discrepancy or failure of a batch or any of its\ncomponents to meet any of its specifications.\"\n\nFollowing that announcement, Medline shares fell approximately 7% on June 2,\n2026.\n\nThen, before market hours on August 5, 2026, Medline acknowledged that at\nleast some of remediation steps taken to address the issues in the FDA's\nwarning letter had \"result[ed] in earnings loss\" during the company's 2Q26\nearnings call.\n\nFollowing that announcement, Medline shares fell approximately 13% on August\n5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in Medline securities, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\n Shareholders are not responsible for any court costs or expenses of\nlitigation.  The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360 and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\"  One testimonial described the firm as \"nimble\nand entrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=1370031417&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/medline-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4784484-1&h=3046498789&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fmedline-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/medline-legal-alert-medline-mdln-investors-who-lost-money-are-notified-of-the-ongoing-securities-fraud-investigation-302891857.html\n(https://www.prnewswire.com/news-releases/medline-legal-alert-medline-mdln-investors-who-lost-money-are-notified-of-the-ongoing-securities-fraud-investigation-302891857.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA2974561\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T10:05:00.094437107Z","server_sent_at_ms":1790676300094},"received_at":"2026-09-29T10:05:00.146Z","source_url":"https://www.prnewswire.com/news-releases/medline-legal-alert-medline-mdln-investors-who-lost-money-are-notified-of-the-ongoing-securities-fraud-investigation-302891857.html"},"analysis":{"id":"143699","press_release_id":"154949","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["FDA warning letter over pharmaceutical manufacturing (CGMP) violations — underlying quality-control issue","Company admitted remediation caused earnings loss; shares fell 13% on August 5, 2026","Ongoing securities-fraud investigation raises litigation and compliance risk"],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP (BFA Law) announced it is investigating Medline Inc. for potential securities fraud related to statements about manufacturing and product quality.\n\nThe release recaps that Medline shares fell roughly 7% on June 2, 2026 after an FDA warning letter citing violations of Current Good Manufacturing Practice regulations, and roughly 13% on August 5, 2026 after the company said remediation steps caused earnings loss on its 2Q26 call.\n\nThis is a law-firm solicitation seeking shareholders to submit information on a contingency basis, not a new filing by the company or a court action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress; the underlying FDA warning letter and 2Q26 remediation costs are the material facts to track."},"keyFigures":{"customDimensions":{"june_2_2026_stock_drop":"7%","august_5_2026_stock_drop":"13%"}},"namedEntities":{"people":[{"name":"Adam McCall","role":"law firm contact"}],"products":[],"companies":[{"name":"Medline Inc.","ticker":"MDLN","relationship":"investigation target"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"prior BFA recovery mentioned in firm marketing"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior BFA recovery mentioned in firm marketing"}],"dollarAmounts":[{"amount":"$900 million","context":"BFA's prior recovery from Tesla's Board of Directors (firm marketing)"},{"amount":"$420 million","context":"BFA's prior recovery from Teva Pharmaceutical (firm marketing)"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Bleichmar Fonti & Auld LLP investigating potential securities fraud claims. No certified class, no settlement, and no new issuer disclosure; the FDA warning letter and stock drops are recaps of prior events."},"tickerRelevance":{"others":[],"primary":"MDLN"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-recent-IPO","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP (BFA Law) announced it is investigating Medline Inc. for potential securities fraud related to statements about manufacturing and product quality.\n\nThe release recaps that Medline shares fell roughly 7% on June 2, 2026 after an FDA warning letter citing violations of Current Good Manufacturing Practice regulations, and roughly 13% on August 5, 2026 after the company said remediation steps caused earnings loss on its 2Q26 call.\n\nThis is a law-firm solicitation seeking shareholders to submit information on a contingency basis, not a new filing by the company or a court action.","key_figures":{"customDimensions":{"june_2_2026_stock_drop":"7%","august_5_2026_stock_drop":"13%"}},"named_entities":{"people":[{"name":"Adam McCall","role":"law firm contact"}],"products":[],"companies":[{"name":"Medline Inc.","ticker":"MDLN","relationship":"investigation target"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","relationship":"prior BFA recovery mentioned in firm marketing"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior BFA recovery mentioned in firm marketing"}],"dollarAmounts":[{"amount":"$900 million","context":"BFA's prior recovery from Tesla's Board of Directors (firm marketing)"},{"amount":"$420 million","context":"BFA's prior recovery from Teva Pharmaceutical (firm marketing)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T10:05:08.191Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap-recent-IPO","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":6737,"modelName":"glm-5.3-flashx"}}